

Cytomegalovirus infection - Pipeline Insight, 2021

<https://marketpublishers.com/r/C87D72611622EN.html>

Date: July 2021

Pages: 100

Price: US\$ 2,000.00 (Single User License)

ID: C87D72611622EN

Abstracts

This report can be delivered to the clients within 72 hours

DelveInsight's, "Cytomegalovirus infection - Pipeline Insight, 2021," report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Cytomegalovirus infection pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Cytomegalovirus infection Understanding

Cytomegalovirus infection: Overview

Cytomegalovirus (CMV) infection is caused by the human cytomegaloviruses. These are a subgroup of infective agents who belongs to the Herpesviridae family and is closely related to the herpes group of viruses. Cytomegalovirus infection is a common herpesvirus infection with a wide range of symptoms including fever and fatigue (resembling infectious mononucleosis), swollen glands, pneumonia with hypoxemia, or low blood oxygen, and sore throat. CMV spreads by direct contact of body fluids, such as saliva, blood, urine, semen, vaginal fluids, congenital infection, and breast milk. Diagnosis of a CMV infection can be confirmed by detection of CMV-induced large inclusion bodies present in urine sediment. The currently available antivirals for CMV therapy works by inhibiting the viral DNA polymerase. The approved treatment includes:

Ganciclovir, valganciclovir, cidofovir, and foscarnet, to treat diseases caused by CMV in immunocompromised patients.

'Cytomegalovirus infection - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Cytomegalovirus infection pipeline landscape is provided which includes the disease overview and Cytomegalovirus infection treatment guidelines. The assessment part of the report embraces, in depth Cytomegalovirus infection commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cytomegalovirus infection collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Cytomegalovirus infection R&D. The therapies under development are focused on novel approaches to treat/improve Cytomegalovirus infection.

Cytomegalovirus infection Emerging Drugs Chapters

This segment of the Cytomegalovirus infection report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Cytomegalovirus infection Emerging Drugs

mRNA-1647: Moderna Therapeutics

mRNA-1647 is a vaccine combining six mRNAs in a single vial, which encode for two antigens located on the surface of CMV: five mRNAs encoding the subunits that form the membrane-bound pentamer complex and one mRNA encoding the full-length membrane-bound glycoprotein B (gB). The vaccine is in Phase II clinical studies for the

treatment of CMV.

Maribavir: Takeda

TAK-620 (maribavir), is an investigational, orally bioavailable, ganciclovir kinase inhibitor based antiviral compound. The FDA has granted Maribavir Orphan Drug Designation for the treatment of clinically significant CMV viremia and disease in at-risk patients. The FDA has also granted maribavir Breakthrough Therapy Designation as a treatment for CMV infection and disease in transplant patients resistant or refractory to prior therapy. In May 2021, Takeda announced that the US Food & Drug Administration (FDA) had accepted a New Drug Application (NDA) for maribavir for the treatment of CMV infection in those that are refractory with or without resistance (R/R), in solid organ transplant (SOT) or hematopoietic cell transplant (HCT) recipients.

Further product details are provided in the report.....

Cytomegalovirus infection: Therapeutic Assessment

This segment of the report provides insights about the different Cytomegalovirus infection drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Cytomegalovirus infection

There are approx. 20+ key companies which are developing the therapies for Cytomegalovirus infection. The companies which have their Cytomegalovirus infection drug candidates in the most advanced stage, i.e. Preregistration include, Takeda.

Phases

DelveInsight's report covers around 20+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Cytomegalovirus infection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

Intravitreal

Subretinal

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Cytomegalovirus infection: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Cytomegalovirus infection therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cytomegalovirus infection drugs.

Cytomegalovirus infection Report Insights

Cytomegalovirus infection Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Cytomegalovirus infection Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Cytomegalovirus infection drugs?

How many Cytomegalovirus infection drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cytomegalovirus infection?

What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Cytomegalovirus infection therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Cytomegalovirus infection and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Moderna Therapeutics

Takeda

AlloVir

SpyBiotech

Trinomab Biotech

Evrys Bio

Merck & Co

Biotest

Stadius Biopharma

Citrarvi Biosciences

Xyphos

Orbis Biosciences

Nobelpharma

Hookipa Biotech

AlphaVax, Inc.

Trellis Bioscience

Key Products

mRNA 1443

Maribavir

Multivirus-specific cytotoxic T lymphocytes

Cytomegalovirus vaccine

Anti-human Cytomegalovirus monoclonal antibody

Research programme: sirtuin targeted therapeutics

V 160

Cytomegalovirus immune globulin

MSC CMV

Research Programme: Herpesvirus vaccines

Research programme: MicAbody antibodies

Ganciclovir extended release

NPC 21

HB-101

AVX601

CMV-345

Contents

Introduction

Executive Summary

Cytomegalovirus infection: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Cytomegalovirus infection – DelveInsight's Analytical Perspective

Late Stage Products (Preregistration)

Comparative Analysis

Maribavir: Takeda

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

V 160: Merck & Co

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis

mRNA-1647: Moderna Therapeutics

Product Description

Research and Development

Product Development Activities
Drug profiles in the detailed report.....
Preclinical/Discovery Stage Products
 Comparative Analysis
Cytomegalovirus vaccine: SpyBiotech
 Product Description
 Research and Development
 Product Development Activities
Drug profiles in the detailed report.....
Inactive Products
 Comparative Analysis
Cytomegalovirus infection Key Companies
Cytomegalovirus infection Key Products
Cytomegalovirus infection- Unmet Needs
Cytomegalovirus infection- Market Drivers and Barriers
Cytomegalovirus infection- Future Perspectives and Conclusion
Cytomegalovirus infection Analyst Views
Appendix

List Of Tables

LIST OF TABLES

- Table 1 Total Products for Cytomegalovirus infection
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Cytomegalovirus infection
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Cytomegalovirus infection - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/C87D72611622EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C87D72611622EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970